Trials / Completed
CompletedNCT07293390
A Clinical Trial of Mass Balance of [14C] TQ05105 in Healthy Chinese Subjects
Mass Balance Study of TQ05105
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To analyze radioactivity excretion and pharmacokinetics in healthy subjects after a single oral dose of \[¹⁴C\]TQ05105, identifying excretion routes, major metabolites, and biotransformation pathways. Secondary: To determine pharmacokinetics of TQ05105 and metabolites (e.g., TQ12550) via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) and assess treatment safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ05105 | Janus Kinase 2 (JAK2) inhibitor |
Timeline
- Start date
- 2024-03-18
- Primary completion
- 2024-04-08
- Completion
- 2024-08-20
- First posted
- 2025-12-19
- Last updated
- 2025-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07293390. Inclusion in this directory is not an endorsement.